Table 1. Baseline characteristics of the participants included in the prospective cohort analyses of amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD).
| Characteristics | Participants in the cohort analysis of ALS | Participants in the cohort analysis of PD | ||
|---|---|---|---|---|
| No. of participants | Mean (SD) or % | No. of participants | Mean (SD) or % | |
| Age at 1st blood sampling, mean (SD), years | 606,421 | 45.93 (15.14) | 587,724 | 50.64 (14.90) |
| Sex, % | ||||
| Male | 310,804 | 51.25 | 300,268 | 51.09 |
| Female | 295,617 | 48.75 | 287,456 | 48.91 |
| Country of birth, % | ||||
| Sweden | 520,478 | 85.83 | 506,484 | 86.18 |
| Other Nordic country | 35,105 | 5.79 | 33,056 | 5.62 |
| Other | 49,564 | 8.17 | 46,933 | 7.99 |
| Unknown | 1,274 | 0.21 | 1,251 | 0.21 |
| Socio-economic status, % | ||||
| Low | 259,794 | 42.84 | 253,763 | 43.18 |
| High | 263,946 | 43.53 | 257,680 | 43.84 |
| Unclassified/missing | 82,681 | 13.63 | 76,281 | 12.98 |
| Inflammatory biomarkers, mean (SD) | ||||
| Leukocyte, 109 cells/L | 201,347 | 6.63 (2.48) | 192,341 | 6.60 (2.27) |
| Immunoglobulin-G, g/L | 132,418 | 11.54 (2.99) | 127,455 | 11.53 (2.94) |
| Haptoglobin, g/L | 401,773 | 1.07 (0.34) | 388,741 | 1.07 (0.34) |
| Uric acid, μMol/L | 491,740 | 289.95 (74.47) | 475,360 | 289.15 (73.78) |
SD: standard deviation